MarketCap
Facebook
X
Telegram
iBio Net Debt | IBIO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt iBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -54.2 M | -5.89 M | -13.7 M | -3.56 M | -22.6 M | -45.6 M | -54.5 M | 20.5 M | 9.15 M | 17.2 M | 2.42 M | -9.49 M | -3.59 M | -4.41 M | -5.62 M | -2.84 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.5 M | -54.5 M | -11.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
59.5 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
14.7 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
612 M | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
-17.8 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-260 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
-107 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-2.07 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
293 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
-29.9 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-127 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
-17.2 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
14.3 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
-89.6 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-41.4 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
-22.5 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
-4.07 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-30.7 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
-15.9 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
19.1 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
-35.6 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
-45 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-38.8 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
173 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
18.7 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-19.8 M | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
-290 M | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
-53.8 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
-76 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
-16.8 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
-59.7 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
-169 M | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
-2.42 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
-46.4 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-47.2 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
-34.5 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-14 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-33.5 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
-184 M | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
-33.6 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
-12.5 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-15.4 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-7.95 M | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
-4.24 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
-4.58 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-4.65 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
-6.38 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
-36.8 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-39 M | - | 1.02 % | $ 90.8 M | Britain |